Physician profile
Pooja Manroa
NPI 1831487552
$1,352.40
in general payments reported to CMS, 2019-2025
16 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.62 · 2020: $63.18 · 2021: $60.88 · 2022: $147 · 2023: $183 · 2024: $240 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $286.38 | 2022-2025 | Evenity, Tepezza |
| Abbott Laboratories | $260.17 | 2022-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $185.93 | 2021-2025 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $124.62 | 2019-2023 | Tepezza |
| Novo Nordisk INC | $115.41 | 2020-2024 | Ozempic, Rybelsus |
| Corcept Therapeutics | $61.91 | 2021-2024 | Korlym |
| Radius Health, INC. | $53.36 | 2023-2025 | Tymlos |
| Mannkind Corporation | $47.03 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $35.38 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.72 | 2024 | |
| Madrigal Pharmaceuticals | $31.86 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $28.08 | 2023 | |
| Averitas Pharma INC. | $25.90 | 2024 | Qutenza |
| Lilly USA, LLC | $25.02 | 2024 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $18.88 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $18.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Manroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.